43 related articles for article (PubMed ID: 36222204)
1. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study.
Yang DH; Wang WP; Zhang Q; Pan HY; Huang YC; Zhang JJ
World J Gastroenterol; 2021 May; 27(17):2025-2038. PubMed ID: 34007137
[TBL] [Abstract][Full Text] [Related]
2. Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog.
Hui VW; Yip TC; Wong VW; Tse YK; Chan HL; Lui GC; Wong GL
Clin Transl Gastroenterol; 2021 Mar; 12(3):e00324. PubMed ID: 33750746
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe.
Patmore LA; van Eekhout KMA; Buti M; Koc ÖM; Agarwal K; de Knegt RJ; Janssen HLA; van der Valk M; Lieveld FI; Hansen BE; Kramer M; de Bruijne J; Claassen MAA; Smit C; de Man RA; Takkenberg B; Carey I; Sonneveld MJ;
J Hepatol; 2024 Feb; 80(2):243-250. PubMed ID: 37898348
[TBL] [Abstract][Full Text] [Related]
4. HCC prediction models in chronic hepatitis B patients receiving entecavir or tenofovir: a systematic review and meta-analysis.
Xu X; Jiang L; Zeng Y; Pan L; Lou Z; Ruan B
Virol J; 2023 Aug; 20(1):180. PubMed ID: 37582759
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of the Fibrosis-4 index and alanine aminotransferase at 1 year of nucleos(t)ide analog treatment for prediction of hepatocellular carcinoma in chronic hepatitis B patients.
Inoue J; Akahane T; Kobayashi T; Kimura O; Sato K; Ninomiya M; Iwata T; Takai S; Kisara N; Sato T; Nagasaki F; Miura M; Nakamura T; Umetsu T; Sano A; Tsuruoka M; Onuki M; Sawahashi S; Niitsuma H; Masamune A;
Hepatol Res; 2024 Feb; 54(2):131-141. PubMed ID: 37621201
[TBL] [Abstract][Full Text] [Related]
6. Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy.
Kim BK; Ahn SH
J Formos Med Assoc; 2023 Dec; 122(12):1238-1246. PubMed ID: 37330305
[TBL] [Abstract][Full Text] [Related]
7. Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs.
Hiyama Y; Fujino H; Namba M; Fujii Y; Uchikawa S; Ono A; Nakahara T; Murakami E; Kawaoka T; Miki D; Tsuge M; Oka S
Hepatol Res; 2024 Mar; ():. PubMed ID: 38539054
[TBL] [Abstract][Full Text] [Related]
8. Assessing efficacy of hepatocellular carcinoma prediction scores to prioritise hepatitis B surveillance in the COVID-19 era.
Sinharay R; Grant AJ; Rivett L; Blackwell R; Mells G; Gelson W
GastroHep; 2021 Mar; 3(2):80-87. PubMed ID: 33821150
[TBL] [Abstract][Full Text] [Related]
9. Risk-stratified approach by aMAP score for community population infected with hepatitis B and C to guide subsequent liver cancer screening practice: A cohort study with 10-year follow-up.
He H; Wu Y; Jia Z; Xu H; Pan Y; Cao D; Zhang Y; Tao X; Zhao T; Lv H; Yi J; Wang Y; Gao Y; Kou C; Niu J; Jiang J
J Viral Hepat; 2023 Nov; 30(11):859-869. PubMed ID: 37723945
[TBL] [Abstract][Full Text] [Related]
10. Deciphering the dual nature of the Fibrosis-4 index in predicting hepatocellular carcinoma risk among hepatitis B patients undergoing nucleos(t)ide analog therapy.
Arai J; Ito K
Hepatol Res; 2024 Feb; 54(2):120-121. PubMed ID: 38126190
[No Abstract] [Full Text] [Related]
11. Comparison of acknowledged hepatocellular carcinoma risk scores in high-risk hepatitis C patients with sustained virological response.
Qiu L; Xu S; Qiu Y; Liu Y; Zhang J
J Viral Hepat; 2023 Jun; 30(6):559-566. PubMed ID: 36890735
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study.
Ishiba H; Sumida Y; Kamada Y; Fujii H; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Takahashi H; Ueda S; Aishima S; Nakajima A; Okanoue T;
J Gastroenterol Hepatol; 2023 Jun; 38(6):896-904. PubMed ID: 36797989
[TBL] [Abstract][Full Text] [Related]
13. Factors Associated with Relapse of Type 2 Diabetes Mellitus after Laparoscopic Sleeve Gastrectomy in Japanese Subjects: A Subgroup Analysis of J-SMART Study.
Watanabe Y; Yamaguchi T; Nagayama D; Tanaka S; Sasaki A; Naitoh T; Matsubara H; Yokote K; Okazumi S; Ugi S; Yamamoto H; Ohta M; Ishigaki Y; Kasama K; Seki Y; Tsujino M; Shirai K; Miyazaki Y; Masaki T; Saiki A; Tatsuno I
Obes Facts; 2023; 16(2):119-130. PubMed ID: 36750042
[TBL] [Abstract][Full Text] [Related]
14. Multicenter, retrospective, cohort study shows platelet counts predict hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease.
Fujii H; Fujii M; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Kawada N; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T;
Hepatol Res; 2023 May; 53(5):391-400. PubMed ID: 36707103
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for liver-related and non-liver-related mortality following a sustained virological response after direct-acting antiviral treatment for hepatitis C virus infection in a real-world cohort.
Kozuka R; Tamori A; Enomoto M; Muto-Yukawa Y; Odagiri N; Kotani K; Motoyama H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Kawada N
J Viral Hepat; 2023 May; 30(5):374-385. PubMed ID: 36583600
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance elastography for the prediction of hepatocellular carcinoma in chronic hepatitis B.
Tamaki N; Higuchi M; Keitoku T; Yamazaki Y; Uchihara N; Suzuki K; Tanaka Y; Miyamoto H; Yamada M; Okada R; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Tsuchiya K; Nakanishi H; Kanto T; Kurosaki M; Izumi N
JGH Open; 2024 Apr; 8(4):e13067. PubMed ID: 38665298
[TBL] [Abstract][Full Text] [Related]
17. Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B.
Ishido S; Tamaki N; Uchihara N; Suzuki K; Tanaka Y; Miyamoto H; Yamada M; Matsumoto H; Nobusawa T; Keitoku T; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Takahashi Y; Tsuchiya K; Nakanishi H; Itakura J; Kurosaki M; Izumi N
JGH Open; 2023 Aug; 7(8):567-571. PubMed ID: 37649865
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
Kaneko S; Kurosaki M; Mashiba T; Marusawa H; Kondo M; Kojima Y; Uchida Y; Fujii H; Akahane T; Yagisawa H; Kusakabe A; Kobashi H; Abe T; Yoshida H; Ogawa C; Furuta K; Tamaki N; Tsuji K; Matsushita T; Izumi N;
J Med Virol; 2023 Jan; 95(1):e28210. PubMed ID: 36222204
[TBL] [Abstract][Full Text] [Related]
19. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
